About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals (NASDAQ:MDGL) is heavily focused on the development of novel therapies aimed at the treatment and management of cardiovascular, metabolic, and liver diseases, with a particular emphasis on nonalcoholic steatohepatitis (NASH). Its most notable project is the development of resmetirom, a thyroid hormone receptor beta agonist designed to address the underlying causes of NASH, including hepatic fat metabolism, inflammation, and fibrosis. The company's objective is to harness cutting-edge science to produce innovative treatments that can significantly improve the lives of patients suffering from these chronic diseases. Through rigorous clinical trials and research, Madrigal Pharmaceuticals aims to pave the way for new standards in the management and treatment of challenging metabolic disorders.
Snapshot
Operations
Products and/or services of Madrigal Pharmaceuticals
- Resmetirom (MGL-3196), an oral thyroid hormone receptor-beta agonist aimed at treating non-alcoholic steatohepatitis (NASH).
- Preclinical programs focused on metabolic-disease targets, including those related to NASH beyond Resmetirom.
- Development of treatments addressing high unmet medical needs in cardiovascular diseases, leveraging their understanding of lipid biology.
- Efforts in improving drug delivery and formulation to enhance the efficacy and safety of their existing pipeline.
- Collaborations with academic and industry partners to explore novel therapeutic approaches in metabolic diseases.
- Initiatives to expand their portfolio through strategic acquisition of promising compounds or technologies in the field of metabolic disorders.
Madrigal Pharmaceuticals executive team
- Mr. William J. SiboldCEO, President & Director
- Dr. Rebecca A. Taub M.D.Founder, Senior Scientific & Medical Advisor and Director
- Ms. Mardi C. DierExecutive VP & CFO
- Ms. Shannon KelleyExecutive VP, Chief Legal Officer & Corporate Secretary
- Ms. Carole HuntsmanExecutive VP & Chief Commercial Officer
- Mr. Mark UnderwoodExecutive Vice President of Business Planning & Operations
- Ms. Rita ThakkarSenior VP & Chief Accounting Officer
- Mr. Ronald FilippoExecutive VP & Chief Information Officer
- Ms. Tina E. VenturaChief Investor Relations Officer
- Mr. Clint WallaceExecutive VP & Chief Human Resources Officer